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PART I
1CLINICAL STUDY ON POSTERIOR UVEITIS
INTRODUCTION
Posterior Uveitis refers to inflammation of retina and or choroid.
Uvea the middle vascular coat of eye consists of iris, ciliary body and
choroid.
 Posterior uveitis is less common than anterior uveitis.The
approximate incidence of 10 - 20 % can be extrapolated from the
literature.
Posterior uveitis with its varied aetiology, varied clinical picture,
associated multiple sequelae and complications signifies the early
diagnosis and prompt treatment. However the disease is associated with
frequent relapses and more protracted course often presenting a clinical
challenge to the treating Opthalmologist,as it is known for gradual
visual loss.
2ANATOMY OF THE UVEAL TRACT
Uvea is the middle vascular coat of the eyeball, consists of iris,
ciliary body and choroid. The term uvea derived from latin word uva
(grape).
Iris
Iris  is  the  anterior  most  part  of  the  uveal  tract  and  forms  the
pupillary diaphragm of the eye.  The anterior surface of iris is divided as
small pupillary zone and large peripheral ciliary zone by the collarette or
minor arterial circle, the thickest part of the iris7. The thinnest most
peripheral portion of the iris, iris root inserted to the middle of the
anterior surface of the ciliary body.
The microscopic structure of iris consists of anterior limiting
layer, iris stroma, anterior pigmented epithelial layer and posterior non
pigmented epithelial layer. Iris  stroma consists of two smooth muscles
sphincter pupillae in the pupillary zone and dilator pupillae in the ciliary
zone.
3Ciliary body
The ciliary body is the middle part of the uveal tract between iris
and choroid. Pars plicata (Corona ciliaris) containing finger like ciliary
processes  is  the  anterior  one  third  of  ciliary  body.   Pars  plana
(Orbicularis ciliaris) is the smooth posterior two thirds of ciliary body.
The microscopic structure consists of supra ciliary lamina, ciliary
body stroma, pigmented epithelial layer, non pigmented epithelial layer
and internal limiting membrane. Ciliary muscle is a non-striated muscle
consists of longitudinal,circular and radial fibres.
The major arterial circle located in the stroma of the ciliary body
and supplies iris, ciliary body and anterior choroid.
Choroid
The choroid is the posterior most part of the uvea that extends
from optic discto ora serrata between RPE and sclera. The microscopic
structure consists of suprachoroidal lamina,stroma, choriocapillaries and
bruch’s membrane .
The stroma consists of collagen, elastic and reticular fibres,
melanocytes, macrophages,mast cells, lymphocytes, plasma cells and
4vessels arranged in two layers as outer layer of large vessels(Haller’s
layer), inner layer of medium vessels(Sattler’s layer) that supply and
drain choroid.
Choriocapillaries consists of  a rich capillary network  which
receives blood from large and medium vessels of stroma. Capillaries
contain fenestrated endothelial cells that allow passage of nutrients to
RPE and outer layers of sensory  retina.
Bruch’s membrane (lamina vitrae) is the innermost layer of
choroid. It is a multilayered structure that lies between the
choriocapillaries and retinal pigment epithelium.
Vitreous Humour
             It is a transparent gel that provides a clear optical medium,
structural integrity to the eye and a pathway for nutrients utilized by the
lens, ciliary body and retina. Vitreous is clear and avascular, filling the
space bound by the lens, retina and optic disc. It occupies approximately
80% of the globe volume. The vireous consists of largely of water
(99%), a network of collagen fibrils, hyaluronic acid, hyalocytes and
mucopolysaccharides, forming a gel like material.
5Retina
It is the innermost layer of eyeball, a thin delicate and transparent
membrane. Retina extends from the optic disc to ora serrata. Grossly on
ophthalmoscopic examination it can be divided into three distinct
regions namely optic disc, macula lutea and peripheral retina.
Microscopic structure of retina consists of 3 types of cells (rods and
cones, bipolar cells, ganglion cells) and their synapses arranged in 10
layers.
Outer four layers of retina viz. retinal pigment epithelium, layers
of rods and cones, external limiting membrane and outer nuclear layer
get their nutrition from the choriocapillaries. Inner six layers get their
supply from the central retinal artery. The fovea is an avascular area
mainly supplied by the choriocapillaries. Inflammation of choroid
always involves the retina secondarily.
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6HISTORICAL REVIEW
1500 BC - Von Hippocrates mentioned the typical findings of
uveitis.
12th century - Mohammed-al-Ghafiqi described a disease with
poliosis, neuralgia and hearing changes.
19th century - Mackenzie described about poor vision after
couching for cataract in same eye and fellow eye
1650- 1730 -  Antoine Maitre Jan described choroiditis for the first
time.
1881 -  Von Michael emphasizedthe importance of
Tuberculosis in uveitis.
1900 -  Neetleship considered a case of exudative choroiditis
to be due to dental   infection.
1906 -  Alfred Vogt and 1929 Koyanagi described bilateral
nontraumatic chronic iridocyclitis associated with
poliosis, vitiligo and dysacousia.
1926 -  Harada described posterior uveitis with exudative
retinal detachment associated with CSF pleocytosis.
1924 -  Shigeta in Japan, 1931- Adamantiades in French and
1937 – Hulsi Bechet reported a multisystem disorder
7with triad of symptoms (recurrent ocular
inflammatory episodes, oral and genital leisons)
1936 -  Sarcoid uveitis associated with facial nerve palsy and
uveoparotid fever was termed as Heerfordt’s
syndrome.
1940 -  Brucellosis and Sarcoidosis were recognized as
clinical entities.
1946 -  Allan C Wood considered that 75% of
granulomatous uveitis was due to Tuberculosis.
1950 -  Toxoplasma uveitis became a proven infection, and
thus parasitic infection played a considerable role in
the aetiology particularly of posterior uveitis.
1950 -  Wilder reported nematode larva in eyes enucleated
for retinoblastoma  and Nichols determined the cause
is toxocara canis.
1952 -  Helenor Campbell Wider identified the Toxoplasma
Gondii in eyes and confirmed it was the cause for
uveitis
1961 -  Wood considered Histoplasmosis to be the cause of
13% of uveitic cases.
8EPIDEMIOLOGY
The incidence of posterior uveitis is less common than anterior
uveitis. Infectious causes are more common in posterior uveitis.
Toxoplasmosis is the most common cause of infectious retinitis in
immunocompetent individuals. CMV retinitis is the most common
opportunistic ocular infection among AIDS patients.
Age incidence
Posterior uveitis can occur in all age groups. The etiology differs
in each age group. Toxocariasis, congenital Toxoplasmosis are common
in children. Toxoplasmosis, white dot syndromes and VKH syndrome
are common in 20-60years. Idiopathic retinal vasculitis and masquerade
syndromes occurin more than 60 years of age2.
Sex incidence
Males are more commonly affected in sympathetic ophthalmia,
Eales disease. Females are more affected in Rheumatoid Arthritis,
Systemic Lupus Erythematosus associated uveitis. There is no gender
predilection for infectious uveitis.
9Duration and laterality
Majority of posterior uveitis is of chronic duration. Most cases of
posterior uveitis are bilateral. Parasitic diseases are typically unilateral.
10
PATHOGENESIS OF UVEITIS
a) Direct Bacterial invasion
One of the oldest and major hypothesis is the concept of direct
bacterial invasion. Another hypothesis for recurrent ocular inflammation
assumes a structural alteration within the eye resulting from a previous
inflammation that predisposes the to recurrent inflammatory episodes2.
b) Prostaglandins
Prostaglandin is a chemical mediator involved in the pathogenesis
of uveitis. Prostaglandin being synthesized by the enzyme prostaglandin
synthetase, cause a dramatic increase in protein content and flare of
aqueous humor and mild smooth muscle contraction (miosis).
c) The uvea as a node
When the antigen is introduced at distant site or is injected
directly into the circulation, antibody production begins inside the eye,
which takes up residence within the uvea and remain for long period.
Here the new antigen is needed to stimulate them for the renewal of the
antibody response.
11
d) Vitreous Antigen depot
Once antigen gain access to vitreous body,it tends to persist and
prolong immune responseto trapped antigen. Since hyalocytes have
macrophagic character, they may promote a persistent tendency to
recurrence of uveitis by processing antigen and modulating the immune
responses.
e) Focal infection
Any focal sepsis is predisposing factor for uveitis since most of
ocular inflammation are infective in nature. Among the foci of infection
the teeth is considered the most profile source. The others being the
tonsils, paranasal sinuses, respiratory tract, alimentary tract, uterus and
urinary tract.
f) Immune response
The major focus now is on the immune characteristics of the eye.
Absence of lymphatic drainage in the eye has special features and plays
a role in the Anterior Chamber Associated Immune Deviation (ACAID).
Uveitis wherein hypersensitivity is dominant, 3 types of reactions must
be considered.
12
1) Immediate Hypersensitivity (Anaphylaxis)
This results from contact of the uveal tissue to some foreign
protein namely bacterial protein, where an immediate antigen antibody
reaction occurs.
2) Delayed Hypersensitivity (Bacterial Allergy)
The tissues are sensitized by contact with living or dead organism
so  that  antibodies  are  formed  on  or  within  cells.  Further  contact  with
same antigen causes severe cellular damage which develops slowly
causing an inflammatory and necrotic tissue reaction causing allergic
iridocyclitis.
3) Immune complex mediated disease
Immune complexes can be demonstrated in the aqueous of
patients with uveitis.e.g, Bechet’s disease. These findings have led to the
speculation that immune complex mediated tissue destruction could
explain intraocular inflammatory disease. Serum complement levels
have also been low in such patients.
13
g)   Autoimmunity
It is an immune response directed against the host. Example is
autoantibody production to the lens. The presence of uveitogenic
antigens in the eye that are capable of inducing disease is an old concept
proposed as early as 1910 by Elschnig. The retina contains these
antigens (SAg) and it is also particularly prone to certain neurotropic
organisms like Toxoplasma Gondii and Herpes viruses.
h) Histo compatibility antigen of uveitis
HLA system is now regarded as the main leucocyte in antigen system.
Some special types of anterior uveitis has been associated with
inflammatory bowel disease like Ulcerative colitis, Crohn’s disaease, the
useful indicator being HLAB27. So there is considerable genetic
variability in susceptibility to the diseases.
14
CLASSIFICATION OF UVEITIS
Anatomical classification (IUSG)
Anterior uveitis           - Iritis
- Iridocyclitis
-   Anterior cyclitis
Intermediate uveitis -  Posterior cyclitis
- Pars planitis
- Hyalitis
- Basal retinochoroiditis
Posterior uveitis -    Choroiditis (focal/multifocal/diffuse)
- Chorioretinitis
- Retinochoroiditis
- Retinitis
- Neuroretinitis
- Retinal vasculitis
Panuveitis
15
Clinical classification
Laterality                     -   Unilateral
                                     - Bilateral
Severity                       -   Mild
                                     - Moderate
                                      - Severe
Chronicity                     -   Acute
-  Acute recurrent
- Chronic
Pattern                             -   Focal
-  Multifocal
-  Diffuse
Pathology                         - Granulomatous
-  Non granulomatosus
Demographics             - Age
 -  Sex
-  Race
16
Aetiological classification
a) Exogenous uveitis : By external injury  to the uvea or invasion of
microorganisms or other agents from outside.
b) Endogenous uveitis : By microorganisms or other agents from
within the patient.
17
POSTERIOR UVEITIS
Posterior uveitis is defined as intraocular inflammation primarily
involving retina and or choroid. In posterior uveitis inflammatory cells
may be observed diffusely through out vitreous cavity, overlying foci of
activeinflammation or in the posterior vitreous face. Macular edema,
retinal vasculitis and retinal or choroidal neovascularization are the
structural complications of posterior uveitis6.
Posterior uveitis encompasses
                     a) Retinitis
                     b) Choroiditis
                     c) Retinal  vasculitis.
Retinitis
 It may be focal, multifocal, geographic or diffuse. Active leisons
characterized by whitish retinal opacities with indistinct border due to
surrounding edema with overlying vitreous cells. As the lesion resolves
the borders become better defined.
18
Choroiditis
It may be focal, multifocal, geographic or diffuse. Active
choroiditis is characterized by a round yellow nodule. It does not usually
induce vitritis in the absence of concomitant retinal involvement. Old
inactive disease appear as atropic chorioretinal leisons with surrounding
hyperpigmentation.
Retinal Vasculitis
 It may occur as a primary condition or as a secondary
phenomenon adjacent to a focus of retinitis.  Veins are more commonly
involved than arteries. Active vasculitis is characterized by yellow or
grey white, patchy perivascular cuffing, retinal hemorrhages and cotton
wool spots. Quiescent vasculitis have perivascular scarring, atropic
retina and pigment epithelial stippling.
19
Aetiology of posterior uveitis
1) Non infectious causes
Collagen vascular diseases – Systemic Lupus Erythematosus,
Polyarteritis nodosa, Microscopic polyangitis and Wegener
granulomatosis.
2) Inflammatory chorioretinopathies of unknown etiology
Inflammatory chorioretinopathies or White dot syndromes are a
heterogenous group of inflammatory disorders with overlapping clinical
features. These include
a) Birdshot retinochoroidopathy
b) Acute posterior multifocal placoid pigment epitheliopathy
c) Serpiginous choroiditis
d) Multifocal choroiditis and panuveitis
e) Punctate inner choroiditis
f) Subretinal fibrosis and uveitis syndrome
g) Multiple evanescent white dot syndrome
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h) Acute retinal pigment epithelitis
i) Acute zonal occult outer retinopathy
3) Infectious causes
a) Viral infections - Herpes simplex and Varicella zoster virus,
Cytomegalovirus, Epstein Barr virus, Rubella, Measles,
Lymphocytic choriomeningitis virus, Westnile virus, Rift
valley fever, Human T cell lymphotrophic virus, Dengue fever
and chikungunya fever
b) Bacterial infections – Tuberculosis, syphilis, Lyme disease,
Leptospirosis, Bartonellosis and Whipple disease
c) Fungal infections – Ocular histoplasmosis syndrome,
Candida, aspergillus and Cryptococcus
d) Protozoal infection – Toxoplasmosis
e) Helminthic infections – Toxocariasis, cysticercosis,
Onchocerciasis and Diffuse unilateral subacute neuroretinitis
4) Post traumatic uveitis
5) Post surgical uveitis
21
Symptoms of posterior uveitis
Floaters and defective vision are the most common symptoms of
posterior uveitis. Floaters result from the shadows cast by vitreous cells
and opacities on the retina.
Defective vision may be caused by the primary effects of uveitis,
such as retinitis or choroiditis directly affecting the macular function or
by the complications of inflammation such as cystoid macular edema,
epiretinal membrane,retinal ischemia,choroidal neovascularization,
opacities in the visual axis from inflammatory cells,fibrin, secondary
cataract, myopic or hyperopic shift from macular edema, protein in
anterior chamber and keratic precipitates inpanuveitis or spill over
anterior uveitis.
Symptoms  due  to  anterior  uveitis  such  as  pain,  redness,
photophobia, watering and decreased vision.
22
Signs of uveitis
In Anterior segment
Keratic precipitates
Inflammatorycells
Flare
Hypopyon
Pigment dispersion
Pupillary miosis
Iris nodules
Synechiae (anterior and posterior)
Band keratopathy (long standing cases)
23
SUN working group grading of Anterior Chamber cells
Cells in field Grade
<1 0
1-5 +-
6-15 1+
16-25 2+
26-50 3+
>50 4+
Grading of aqueous flare
Description Grade
Nil 0
Just detectable 1+
Moderate ( iris & lens details clear ) 2+
Marked ( iris & lens details hazy ) 3+
Intense ( fibrinous exudate ) 4+
24
Keratic precipitates (KPs)
These are small aggregates of inflammatory cells that accumulate
on  the  endothelial  surface  on  cornea.  It  indicates  current  level  of
inflammatory activity, mostly found in lower half of  cornea in a base
down triangle configuration between 4 and 8’o clock position an area
termed as Arlt’s triangle2.
KPs are categorized on the basis of
Size -  small / medium / large
Shape and colour  -  white and round (fresh)
                              - Shrunken and pigmented (old)
Appearance - mutton fat KPs (Granulomatous)
-  White and round (Non granulomatous)
Perfield Grading
5-10 1+
11-20 2+
20-50 3+
>50 4+
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Signs in posterior segment
Retinal or choroidal inflammatory infiltrate
Inflammatory sheathing of arteries or veins
Exudative, tractional or rhegmatogenous retinal detachment
Retinal pigment epithelial hypertrophy or atrophy
Swelling or atrophy of retina, choroid or optic nerve head
Preretinal or subretinal fibrosis
Retinal or choroidal neovascularization
Grading of vitreous cells ( Hruby lens )
Cells in
retroilluminated field
Description Grade
0-1 Clear 0+
2-20 Few opacities Trace
21-50 Scattered opacities 1+
51-100 Moderate opacities 2+
101-250 Many opacities 3+
>251 Dense opacities 4+
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Examination of the anterior vitreous is done with a slit lamp by
rotating the slit 45 degrees and rotating the slit or illumination arm at the
minimum angle of separation from the viewing pathway.
Vitreous haze is a better indicator of active inflammation than are
vitreous cells because it combines the optical effect of cellular
infiltration and protein leakage. Grading of vitreous haze is done by
comparing the patient examination by indirect ophthalmoscope with
standard colour photograph in the examination room.
Grading of vitreous haze
Haze severity Grading
Good view of nerve fibre layer 0
Clear disc & vessels but hazy NFL 1+
Disc and vessels hazy 2+
Only disc visible 3+
Disc not visible 4+
27
Examination of Retina and Choroid
Examination of retina and choroid are done with combination of
indirect ophthalmoscope, Hruby lens, + 90 diopter lens, mirrored
contact lens. The indirect ophthalmoscope is ideal for defining the
extent and height of retinal and choroidal leisons, to find out peripheral
vascular sheathing, narrowing, obliteration and deep isolated choroidal
leisons. Hruby lens +90 diopter lens are useful to determine the depth of
the lesion. Mirrored contact lens are useful to look for the midperiphery
of retina.
28
Complications of posterior uveitis
Cystoid Macular edema (CME)
It is a common cause of visual loss in posterior uveitis . Macular
edema is caused by active intraocular inflammation that leading to
retinal vascular leakage and retinal pigment epithelial dysfunction. CME
is quantitatively evaluated and followed by serial spectral domain OCT
and Fundus Fluorescein Angiography.
A recent study of uveitic macular edema divided the edema
morphologically into diffuse macular edema, cystoid macular edema
and serous retinal detachment.
Retinal detachment
Rhegmetogenous retinal detachment and Tractional retinal
detachment are common in posterior uveitis. Infectious uveitis and
panuveitis are more frequently associated with rhegmatogenous retinal
detachment(RRD).Uveitis is usually still active with retinal detachment.
Upto 30% of patients with RRD may have proliferative
vitreoretinopathy at presentation. Repair is difficult due to preexisting
PVR, vitreous organization and poor visualization.
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Vitreous opacification and Vitritis
Permanent vitreous opacification affects the vision. It is treated
with  3- port pars plana vitrectomy.
Proliferative retinopathy
Retinal neovascularization occurs from chronic inflammation or
capillary non perfusion. It is commonly seen in retinal vasculitis of
various causes and sarcoid panuveitis.
Choroidal neovascularization
Choroidal neovascularization results from a disruption of the
Bruch membrane from choroidal inflammation and the presence of
inflammatory cytokines that promote angiogenesis. It is commonly
occur in ocular Histoplassosis syndrome, puntate inner choroidopathy,
idiopathic multifocal choroiditis and serpiginous choroiditis. It can be of
foveal, juxta foveal, extrafoveal and peripapillary types.
Other complications due to spill over anterior uveitis
Secondary glaucoma
Complicated cataract
Hypotony
30
Aetiologyof posterior uveitis
Ocular Toxoplasmosis
Toxoplasmosis is the most common cause of infectious
retinochoroiditis in immunocompetent adults and children. Classically
presents as new unilateral white yellow retinal lesion with overlying
moderate vitreous inflammation (headlight in the fog), often adjacent to
a pigmented chorioretinal scar with perivasculitis and diffuse venous
sheathing of adjacent retinal vessels. Most of the leisons occurs in the
posterior pole.
Diagnosis is made clinically and serological evaluation using
ELISA test used to confirm the exposure to parasite. Treatment regimen
is classical triple therapy (systemic prednisolone, pyrimethamine and
sulfadiazine). Alternative regimens are co-trimaxozole or azithromycin
with systemic corticosteroids.
Tuberculosis
Uveitis is the most common manifestation of secondary ocular
TB. Tuberculous uveitis is classically a chronic granulomatous disease
that affect anterior and posterior segments.
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Disseminated choroiditis is the most common presentation
characterized by deep, multiple, discrete, yellow leisons between 0.5
and 3 mm diameter located predominantly in posterior pole associated
with disc edema, vitritis, granulomatous anterior uveitis. Other
presentation  single, focal, large, elevatedchoroidal mass (tuberculoma)
of 4-14 mm in size.
Other posterior segment findings of TB includes subretinal
abscess, CNV, optic neuritis and acute endophthalmitis. Retinal
involvement present as Eales disease and peripheral retinal
perivasculitis.
Cytomegalovirus retinitis
Cytomegalovirus is an opportunistic pathogen in
immunocompromised individuals and the most common infection in
AIDS typically occurs when the CD4 count is <50 cells/microliter.
Cytomegalovirus retinitis is characterized by greyish patches or
scaterred white dots with irregular sheathing of adjacent blood vessels.
There are superimposed haemorrhages followed by healing and retinal
atrophy. Ganciclovir is used in the treatment of CMV retinitis.
32
Toxocariasis
Ocular toxocariasis is an uncommon disease of children and
young adults that causes significant visual loss. It is acquired by
ingestion of soil containing eggs of the canine intestinal round worm
Toxocara canis. It otherwise involves healthy individualswith a normal
white cell count and absence of eosinophilia. It is unilateral and in
children it presents as chronic endophthalmitis and posterior pole
granuloma. In adolescence or adult life it presents as peripheral retinal
granuloma associated with a vitreous band extending to the disc or
macula causing visual impairment.
Lab diagnosis is by the high sensitivity and specificity (90%) of
an ELISA titre for Toxocara. Oral or periocular corticosteroids are used
for treatment.
Noninfectious autoimmune diseases
These are the collagen vascular diseases namely Systemic lupus
erythematotosus , Polyarteritis nodosa and Microscopic polyangitis and
Wegener granulomatosis.
33
Systemic lupus erythematosus
It is a connective tissue disorder with multisystem involvement
that primarily affects women of child bearing age. Ocular involvement
occur in 50% of cases and include cutaneous leisons on eyelids, sjogren
syndrome, scleritis, cranial nerve palsies and retinal vasculopathy.
Lupus retinopathy is an important marker of systemic disease
activity. The clinical spectrum is characterized by cotton wool spots
with or without intraretinal hemorrhages due to microangiopathy, severe
retinal vascular occlusive disease resulting in retinal nonperfusion and
ischemia, secondary retinal neovascularization and vitreous hemorrhage,
lupus choroidopathy resulting in serous elevations of retina, choroidal
infarction and choroidal neovascularization.
The diagnosis is essentially clinical based on revised diagnostic
criteria. Antinuclear antibody anti- ds DNA antibody (anti double
stranded deoxyribo nucleic acid antibody) and antiphospholipid
antibodies are positive in SLE.
 Treatment is control of underlying disease with NSAIDS (Non
steroidal anti-inflammatory drugs), Corticosteroids and
34
immunosuppressive drugs. Ischemic complications are managed with
panretinal photocoagulation and vitrectomy surgery.
Polyarteritis nodosa and microscopic polyangitis
Polyartertis nodosa is an uncommon systemic vasculitis
characterized by subacute or chronic, focal,episodic necrotizing
inflammation of medium sized and small muscular arteries. It is seen in
patients between the ages of 40-60 years. Ocular involvement seen in
20% of patients includes hypertensive retinopathy, retinal arteriolar
occlusive disease, choroidal infarcts with exudative retinal detachment
secondary to vasculitis involving posterior ciliary arteries and choroidal
vessels, cranial nerve palsies and peripheral ulcerative keratitis with
scleral involvement. pANCA (perinuclear antineutrophil cytoplasmic
antibody)is positive in Polyarteritis nodosa and microscopic
polyangitis.Treatment consists of systemic corticosteroids and
immunomodulators6.
Wegener granulomatosis
It is a multisystem autoimmune disorder characterized by the
classic triad of necrotizing granulomatous vasculitis of upper and lower
respiratory tract, focal segmental glomerulonephritis and necrotizing
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vasculitis of small arteries and veins. Ocular or orbital involvement seen
in 15% of cases. Orbital involvement is secondary to contiguous
extension of the granulomatous inflammatory process from the
paranasal sinuses.
Ocular involvement includes unilateral or bilateral anterior,
intermediate or posterior uveitis, with varying degrees of vitritis and
retinal vasculitis leading to retinal neovascularization, vitreous
hemorrhage and neovascular glaucoma. c ANCA (cytoplasmic
antineutrophil cytoplasmic antibody)positivity is sensitive and specific
for Wegener granulomatosis. Treatment includes systemic
corticosteroids and immunosupressants.
Eales disease
It is an idiopathic, inflammatory peripheral retinal vasculopathy
which presents with recurrent vitreous hemorrhages in young males. It
has been suggested that a hypersensitivity of retinal vessels to
tuberculoproteins may be the cause for retinal vasculitis. The vasculitis
leads to obliteration of affected vessels, subsequent hypoxia and
vasoproliferation.
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It is clinically seen as sheathing of the vessels, which leaks
copiously on FFA. Hemorrhages , soft exudates and retinal edema are
common at the junction of perfused and non perfused zones of retina. In
proliferative stage it presents as recurrent vitreous hemorrhages, vitreous
traction and retinal detachment.
Treatment of acute vasculitic stage consists of systemic steroids.
Proliferative stage is treated with retinal photocoagulation and
vitreoretinal surgery.
White dot syndromes
The inflammatory chorioretinopathies or white dot syndromes are
a heterogenous group of inflammatory disorders with overlapping
clinical features that share in common the presence of discrete, multiple,
well circumscribed, yellow white leisons at the level of retina, outer
retina, RPE, choriocapillaries and choroid during some phase of their
course. These consists of predominantly non infectious ocular
syndromes.
Common presenting symptoms include photopsias, blurred vision,
nyctalopia, floaters and visual field loss contiguous with a blind spot.
The syndromes are bilateral and asymmetrical in nature. The etiology of
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the white dot syndromes is unknown. Infectious, autoimmune and
infiammatory pathogenesis has been postulated for these disorders.
Panuveitis
Panuveitis is defined as inflammation involving all anatomical
compartment of eye (anterior chamber, vitreous and retina or choroid)
with no single predominant site of inflammation.It is usually bilateral.
Common causes are
a) Vogt – Koyanagi – Harada syndrome
b) Sarcoidosis
c) Sympathetic ophthalmia
d) Behcet disease
e) Infectious causes – Tuberculosis, Syphilis
Vogt –Koyanagi-Harada syndrome
It is an uncommon multisystem disease of presumed autoimmune
etiology that is characterized by chronic, bilateral, diffuse
granulomatous panuveitis with accompanying integumentary,
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neurological and auditoryinvolvement. There are four stages of VKH
syndrome: prodromal, acute uveitic, convalescent and chronic recurrent.
Acute uveitic stage characterized by sequential blurring of vision
in both eyes with bilateral granulomatous anterior uveitis,variable
degree of vitritis, thickening of the posterior choroid, hyperemia and
edema of disc and multiple serous detachments. The chronic phase
shows diffuse RPE atrophy (sunset glow fundus).Complications include
CNV and subretinal fibrosis.
FFA of the acute phase shows multifocal hyperfluorescent dots at
the level  of  RPE and then accumulation of  dye in the subretinal  space.
The chronic phase shows are areas of hyperfluorescence due to RPE
window defects.
Treatment involves high dose oral prednisolone (60-100mg/day)
that may be augmented with 3 days intravenous pulse therapy with
methyl prednisolone (500-1000mg/day).Steroid resistant patients require
immunosupreesive therapy. Topical Corticosteroids and topical
cycloplegics for anterior uveitis.
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INVESTIGATIONS
There is no one standardized battery of tests that need to be
ordered for all patients with posterior uveitis. Rather a tailored approach
should be taken based on the most likely causes for each patient. Once a
list of differential diagnosis is compiled appropriate laboratory tests can
be ordered. Many patients require only one or a few diagnostic tests6.
If the history and clinical examination do not clearly indicate any
cause, purified protein derivative skin test, chest radiograph, chest
computed tomography, serum angiotensin converting enzyme and
syphilis serologies are done to rule out the most common causes
(Tuberculosis, Syphilis and Sarcoidosis).
Laboratory tests and imaging studies with indications
Test Indications
HEMATOLOGICAL TESTS
Complete blood count Immunomodulator therapy
Erythrocyte sedimentation rate Gaint cell arteritis
Quatiferon gold Tuberculosis
T cell subsets  AIDS
SEROLOGICAL TESTS Indications
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Liver function test Immunomodulator therapy,
sarcoidosis
Renal function test Immunomodulator therapy
Angiotensin converting enzyme Sarcoidosis
Antiphospholipid antibodies Vascular occlusion
Rheumatoid Factor Rheumatoid arthritis, juvenile
idiopathic arthritis
Antinuclear antibody Connective tissue diseases
HLA testing
HLA-B27 Seronegative spondyloarthropathy
HLA-A29 Birdshot retinochoroidopathy
HLA-B51 Bechet disease
ANCA (c ANCA and p ANCA) Systemic vasculitides
VDRL/RPR Syphilis
FTA ABS Syphilis
Toxoplasma antibodies Toxoplasmosis
HSV,VZV,CMV serology Viral uveitis
HIV serology/ Westernblot HIV/AIDS
Radiographic studies Indications
Chest radiograph Tuberculosis, sarcoidosis, wegener
granulomatosis
Sacroiliac joint Ankylosing spondylitis
CT chest Sarcoidosis
CT/MRI brain and orbits Sarcoidosis, toxoplasmosis
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Complete blood count and differential count
It is done to determine whether there isacute or chronic
inflammation.  Complete blood count is obtained before initiating
systemic therapy with either corticosteroid or immunosuppressive drugs.
Erythrocyte sedimentation rate
It is a non-specific indicator of plasma fibrinogen and globulin
levels and may be elevated in systemic infection or inflammation or
malignancy. It is done using Westergren method.
Rheumatoid Factor
Rheumatoid Factor (RF) is an autoantibody directed against the
Fc fragment of human IgG. About 80% of Rheumatoid Arthritis patients
are  RF  seropositive,  defined  as  a  titre  of  more  than  1:80.  RF
seropositivity is non specific and best to support a clinical diagnosis of
Rheumatoid Arthritis.
Antinuclear Antibodies (ANA)
The ANA test is typically performed by applying serial dilutions
of the patients serum to cultured tumor cells and then titrating for the
presence and pattern of nuclear antibody staining. The ANA test is
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generally used to confirm collagen vascular disease particularly
Systemic Lupus Erythematosus or Juvenile Rheumatoid Arthritis.
Herpes Virus antibodies
The prevalence of Herpes virus antibodies is so high in the
general population that a positive antibody titre is virtually meaningless.
A negative titre , however eliminates herpes infection and therefore can
be useful in selected instances.Herpes virus serology should remain
positive for life.
HIV antibodies
Most commonly detected by using an Enzyme Linked Immuno
Sorbent Assay (ELISA), positive results are confirmed by a westernblot
test. HIV testing in uveitis is usually orderedin patients with known HIV
risk factors, severe or bilateral retinitis or choroiditis. HIV testing
requires patient consent.
Toxoplasma antibodies
Tests available to detect and quantify antitoxoplasma gondi
antibodies are sabin Feldman dye test(SF), Immuno Fluorescence
Antibody (IFA) test and ELISA. Of these SF dye test remains the most
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sensitive and specificbut it is technically difficult and of limited
availability, where as IFA ana ELISA are relatively easy and
economical and can be used to distinguish IgG and IgM anti
Toxoplasma gondii antibodies. When interpreting positive titres, it is
important to remember that IgM anti Toxoplasma antibodies may be
elevated for upto 1 year after infection, limiting the accuracy with which
they can date acute infection and that antibody titres are generally less
reliable in patients with AIDS.
Angiotensin Converting Enzyme level (ACE)
ACE is produced primarily by capillary endothelial cells,
abundant in both lungs and liver, and by macrophages. Clinically, ACE
levels  are  elevated  in  more  than  two  thirds  of  patients  with  a  active
disease of sarcoidosis.
Uveitis and negative Purified Protein Derivative (PPD) with
increased ACE is fairly specific for sarcoidosis. Normal serum ACE
level is 12-55mol/min/ml in men and 11-19 mol/min/ml in women.
Human Leucocyte Antigen (HLA) study
The surface membrane of human leucocyte contain HLA. These
are regulated by gene loci on chromosome 6. The reaction of these
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antigens with specific antisera cause lysis of the cell membrane and this
is  the  basis  of  cell  typing.  HLAB27  has  been  associated  with
Ankylosing spondylitis and Reiter’s syndrome.
Mantoux test
Purified protein derivative of tuberculin is injected intradermally.
It  is  a  non-specific  test.  Because  of  prior  exposure  to  tuberculosis,  a
large number(8 to 30%) of healthy adults have positive PPD skin test
representing inactive infection. Therefore it is disadvantageous as it
yields more false positive than true positive results.
X ray chest and X ray sacroiliac joints
Chest x ray is taken in patients suspected by having sarcoidosis or
tuberculosis. X ray sacroiliac joints is taken in patients also complaints
of joint pains and hip pains.
Fundus Fluorescein angiography
It is an essential modality for evaluation of posterior uveitis. It is
useful for both diagnosis and monitoring patient’s response to therapy.
Areas of choroidal, retinal and optic nerve inflammation, cystoid
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macular edema, retinal vasculitis, secondary choroidal and retinal
neovascularization are detected angiographically.
Ultrasonography
It is useful in demonstrating vitreous opacities, choroidal
thickening, retinal detachment or cyclitic membrane formation,
particularly if media opacities preclude a view of posterior segment6.
Optical coherence tomography
It is used for the objective measurement of uveitic cystoid
macular edema, retinal thickening, subretinal fluid associated with
choroidal neovascularization and serous retinal detachment.
Indocyanine green angiography
It shows 2 patterns of hypofluorescence in inflammatory
choroidal vasculopathies. Type 1 in inflammatorychoriocapillaropathies
demonstrate early and late multifocal areas of hypofluorescence. Type 2
represents stromal inflammatory vasculopathies of choroid and
demonstrates areas of early hypofluorescence and late
hyperfluorescence.
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TREATMENT
Mydriatic and Cycloplegic agents
Topical mydriatic and cycloplegic agents are beneficial for
breaking or preventing theformation of posterior synechiae  and for
relieving photophobia secondary to ciliary spasm in spill over anterior
uveitis or panuveitis. The stronger the inflammation, the stronger or
more frequent the dose of  cycloplegic. Short acting drugs such as
cyclopentalate hydrochloride 1% or long acting drops such as atropine
0.1% may be used.
Corticosteroids
Corticosteroids are the mainstay of posterior uveitis therapy. It
may given in topical, periocular or systemic routes.
Topical steroids
Topical steroids are effective primarily for anterior uveitis. 1%
prednisolone acetate eye drops started as hourly, once the inflammation
is controlled , frequency gradually tapered to 2 hourly, 3 hourly then 4
times a day, eventually reduced by one drop a week until it reaches one
drop day. The drops discontinued within 5- 6 weeks. Complications are
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elevation of IOP, cataract and uncommon complications are secondary
corneal infection, cornea melting.
Periocular steroids
Periocular steroids are given as first line therapy to control
inflammation and macular edema in unilateral posterior uveitis, to
supplement systemic therapy or when systemic steroids are
contraindicated in bilateral posterior uveitis. It delivers a therapeutic
dose of medication close to site of inflammation. Triamcinolone
acetonide (40mg) or methylprednisolone acetate (40-80mg) are most
commonly used drugs.
Periocular injections can be given through transseptal or subtenon
(Nozik technique) approach either in superotemporal (preferred) or
inferotemporal quadrant. Patient is instructed to look down and nasally,
after anesthesia is applied with a cotton swab soaked in proparacaine ,
needle is placed bevel down against the sclera and  advanced through
the conjunctiva and tenon capsule using side to side movement upto the
hub,then drug is injected into the subtenon space.
Complications are ptosis, globe perforation, periorbital or
retrobulbar hemorrhage, orbital fat atrophy, skin discoloration
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andelevation of IOP for long time. Periocular injections are
contraindicated in infectious posterior uveitis.
Systemic corticosteroids
Systemic steroids are used in vision threatening posterior uveitis,
panuveitis or when systemic disease also requires therapy. Prednisolone
is the most commonly used drug. Start with a large dose and then
reduce. The starting dose of prednisolone 1-2mg/kg/ day given in a
single morning dose after breakfast. A high level is maintained until a
clinical effect is seen followed by a slow taper over every 1-2 weeks
until the disease is quiescent. The lowest possible dose that will control
inflammation and minimize side effects is desired. This dose should be
5-10mg/day. If dose greater than this is required or treatment required
for longer than 3 months, steroid sparing immunomodulator therapy is
indicated.
In explosive onset of severe non infectious posterior uveitis or
panuveitis intravenous high dose pulse methylprednisolone (1g/day
infused over 1 hour) therapy may be administered for 3 days followed
by a gradual taper of oral prednisolone.
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Side effects of short term therapy includes dyspepsia, mental
changes, electrolyte imbalance and aseptic necrosis of the head of
femur. Side effects of long term therapy includes cushingoid state,
osteoporosis, reactivation of infections, cataract and exacerbation of
diabetes and myopathy.
Contraindications are poorly controlled diabetes, peptic ulcer,
osteoporosis, active systemic infection, psychosis on previous exposure
to steroids.
Intravitreal administration
1) Intravitreal injections
2) Intravitreal implants
Intravitreal injection of preservative free triamcinolone acetonide
through single trans pars plana route, 4mg/0.1ml given for recalcitrant
uveitic cystoid macular edema and choroidal neovascularization. It
produces sustained improvement in visual acuity for 3-6 months.
Intravitreal sustained release implants (fluocinolone acetonide
0.59mg, dexamethasone-ozurdex 350/700 microgram) are given for non
infectious posterior uveitis. Early post operative complications are
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endophthalmitis, wound leak, vitreous detachment and retinal
detachment.Cataract and secondary glaucoma are the late common
complications2.
Immunomodulators
Antimetabolites, inhibitors of T cell signaling, alkylating agents
and biological response modifiers are the commonly used
immunomodulators.
Indications for immunomodulators in posterior uveitis are
? Severe vision threatening posterior uveitis
?  Patients resistant to or cannot tolerate corticosteroids,
?When corticosteroids are contraindicated due to systemic
problems
?  Patient requires chronic corticosteroid therapy (longer than 3
months) at doses greater than 5-10 mg/day
? Chronic topical corticosteroid dependence and those who
requiring multiple periocular corticosteroid injections.
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Corticosteroids are the mainstay of initial therapy, but early use of
immunomodulator therapy is indicated in certain specific uveitis
(Serpiginous choroiditis, VKH, Bechets disease and
sympatheticophthalmia) to improve the long term prognosis and tovisual
morbidity. Before initiating the therapy, infections, hepatic and
hematologic contraindications should be ruled out.
Therapeutic effect of immunomodulators will start only after
several weeks. So patients should be maintainedon corticosteroids until
the immunomodulators begin to take effect, at that timecorticosteroid
dose gradually tapered.
Immunomodulatory drugs in posterior uveitis
Medications Dosage Complications
Antimetabolites
Methotrexate 7.5-25
microgram/week
Hepatotoxicity, GI upset
Azathioprine 100-250mg/day Hepatotoxicity, GI upset
Mycophenalate
mofetil
1-3 g/day GI ulceration, diarrhea
Inhibitors of T cell
signaling
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Cyclosporine 2.5-5mg/kg/day Nephrotoxicity,hypertension
Tacrolimus 0.1-0.2mg/kg/day Nephrotoxicity,hypertension
Sirolimus 6mg iv loading
dose, 4mg/day iv
increased by 2mg
increments
GI upset
Alkylating agents
Cyclophosphamide 1-2mg/day Hemorrhagic cystitis, sterility
Chlorambucil 2-12mg/day Hemorrhagic cystitis, sterility
Biological
response modifiers
Infliximab 3mg/kg iv 0,2,6
weeks then once
in 6-8weeks
Infusion reactions, infections,
malignancy
Adalimumab 40mg/week Headache, GI upset
Daclizumab 1mg/kg iv once in
two weeks 5 doses
Rituximab Two doses 1g iv
two weeks apart
Late onset neutropenia
Complications include hepatic and renal toxicity, bone marrow
suppression and increased susceptibility to infections. Patients should be
monitored with complete blood count, liver and renal function test
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regularly. These agents are teratogenic, so patients should be advised to
avoid pregnancy during treatment.
Treatment of Infectious posterior uveitis
Infectious posterior uveitis is treated with systemic antimicrobial
drugs and systemic corticosteroids. Antibiotics, antiviral drugs,
antifungal drugs, anti parasitic agents are the antimicrobial drugs used in
posterior uveitis. The choice of antimicrobials depends on the etiology
of posterior uveitis.
Treatment of sequelae and complications
Secondary glaucoma is treated with antiglaucoma medications.
Topical corticosteroids and aqueous suppressants are administered
topically and acetazolamide is given systemically. Pilocarpine and
prostaglandin analogues are contraindicated in uveitic glaucoma.
Cataract are removed surgically after uveitis is quiescent for
atleast 2-3 months. Cystoid macular edema is treated with meticulous
control of intraocular inflammation with corticosteroids,
immunomodulator drugs and periocular  steroids.
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Proliferative retinopathy is treated with laser photocoagulation.
Permanent vitreous opacification affecting vision is treated with 3– port
pars plana vitrectomy. Rhegmatogenous retinal detachment is treated
with scleral buckling with cryoretinopexy, pars plana vitrectomy and
endolaser with silicone oil tamponade or combined scleral buckling and
pars plana vitrectomy. But the prognosis is poor . Retinal and Choroidal
neovascularization are treated with control of inflammation using
corticosteroids and immunomodulators, focal laser photocoagulation
and intravitreal injectionof bevacizumab.
In spite of all treatment modalities 10% patients will develop
permanent loss of vision. More so the patients with systemic association
of diseases, treatment of posterior uveitis and restoration of vision is a
challenge to all Ophthalmologists.
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REVIEW OF LITERATURE
? Ocular  toxoplasmosis  is  one  of  the  most  common  type  of
Posterior uveitis of infectious origin comprising 30- 50% of
cases. Pyrimethamine and sulfadiazine with corticosteroids is the
classical chemotherapy most widely used in the treatment for
ocular toxoplasmosis. An alternative treatment with
Trimethoprim/sulfamethoxazole plus oral prednisolone showed
to have similar efficacy to classical therapy (de-la-Torre A et al
Therapy for ocular toxoplasmosis. Ocul Immunol Inflamm.
2011;19:314–320)8.
? In  a study conducted by Anna Elias et a, the mean age
presentation  of  VKH  Syndrome  was  37.26  years.   Majority  of
patients  had exudative retinal detachment, followed by optic dis
edema and anterior uveitis. Fundus fluorescein angiography
(FFA)showed multiple pinpoint hyperfluorescent leaks at the
level of the retinal pigment epithelium in all patients. All patients
were treated with systemic steroids.  17.39% patients were also
treated with immunosuppressants. 5.26% patients developed
subretinal fibrosis and 5.26% patients developed secondary
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glaucoma  89.47% had a final visual acuity better  than 6/12.The
eyes with secondary glaucoma responded to topical anti-
glaucoma meditations.
? The more common manifestation of ocular tuberculosis is chronic
granulomatous iridocyclitis with multifocal posterior choroiditis.
Choroidal granuloma is an atypical presentation for ocular
tuberculosis and is less commonly reported.Patients are treated
with category I ATT for total 6 months duration and Choroidal
nodular lesion will resolve completely after 8 weeks of starting
Anti-tubercular chemotherapy, with BCVA improving  to 20/20.
(Laurent J et al Arch Ophthalmol. 2005;123:864-866 )19.
? The most frequent clinical  presentation of Eales' disease is a
sudden painless loss of vision because of vitreous hemorrhage.
Corticosteroids remain the mainstay of the treatment in the active
perivasculitis stage of Eales' disease. Laser photocoagulation is
the mainstay of treatment in the proliferative stage of Eales'
disease.  Fluorescein angiography helps in monitoring the
response to treatment. (Abu El-Asrar and Al-Kharashi Br J
Ophthalmol 86:1248-1251)23.
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? Serpiginous choroidopathy occur typically at the disc and spread
in a helicoid pattern along the major vascular arcades towards the
macula.Combination azathioprine and systemic corticosteroids is
a safe and acceptable treatment . Recurrences are common and
manifest as yellow-grey extensions at the level of the
choriocapillaris, contiguous or as satellites to existing areas of
chorioretinal atrophy . Visual disability may result directly from
retinal lesions affecting the central macula, or from secondary
choroidal neovascularization (Jampol LM et al Am J Ophthalmol
88:683–689).
? CMV retinitis is one of the most common complications of AIDS
patients, it can affect 6 to 38% of patients and may be bilateral in
30 to 50% with up to 25% of the affected patients possibly losing
their  vision  (  Holland  GN,  et  al  . American Journal of
Ophthalmology, 114: 86-95).
? Ocular toxocariasis  is relatively uncommon,occurring in1% of
uveitis. Clinical presentation is unilateral (90.9%). Ocular
Toxocarasis is   characterized by a granuloma in the peripheral
retina in 50% of cases, granuloma in the macula in 25% of cases,
and severe vitreous inflammation mimicking endophthalmitis in
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25% cases. The primary causes of poor vision are cystoid
macular edema (47.4%), and traction retinal detachment (36.8%).
The mainstay of  treatment of Toxocariasis is corticosteroids to
reduce inflammatory responses  (Smith H et al Trends Parasitol
25: 182–188. doi: 10.1016/j.pt.2009.01.006) .
? Ocular  manifestations in SLE may be vision threatening and is
indicator of active systemic disease. The mainstay of treatment is
systemic corticosteroids and immunosuppressive
drugs.Proliferative retinopathy is treated with  panretinal
photocoagulation Giorgi D et al.
PART II
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AIM OF THE STUDY
To  analyse  the  posterior  uveitis  with  reference  to  age  and  sex
incidence, laterality, etiology, chronicity, severity, clinical presentation,
sequelae,  complication and treatment modalities.
Primary objective
• To evaluate the various etiological factors and predisposing
factors leading on to posterior uveitis.
• To assess the clinical presentation in different types of posterior
uveitis.
• To diagnose and start treatment after systematic evaluation
Secondary objective
• To  assess  visual  outcome  after  treatment  of  Posterior  Uveitis
since Posterior uveitis treatment is a challenge to all
Ophthalmologists.
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MATERIALS AND METHODS
The study design was a prospective study of 30 patients  with age
range of 20-45 years with posterior uveitis, conducted in Regional
Institute of Ophthalmology and Ophthalmic Eye Hospital during August
2013 to August 2014 for a period of 12 months.
Main criteria for diagnosis
1)  Patients having whitish retinal opacities with indistinct borders
(focal/multifocal/diffuse) and vitritis suggestive of retinitis
2)  Patients having round yellowish nodule in the fundus
(focal/multifocal/diffuse) suggestive of choroiditis
3)  Patients having yellow or grey white, patchy perivascular cuffing
suggestive of active vasculitis
4)  Patients having papillitis with multiple serous detachment
suggestive of  VKH syndrome
5)  Patients having peripheral tubercles
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Exclusion criteria
1)  Post surgical cases
2)  Post trauma cases
3)  Intermediate uveitis ( predominant vitritis without active
chorioretinal lesion)
4)  Predominant anterior segment involvement without active
chorioretinal lesion)
5)  Patients who lost follow up.
All these patients were questioned about thepresenting compliants
(floaters, defective vision), history of contact with pets, tuberculosis,
joint pain and focal sepsis.
Systemic examination of cardiac, pulmonary, gastrointestinal,
central nervous system and musculoskeletal system was done.
Complete ocular examination including visual acuity using
Snellen’s acuity chart, slit lamp examination of the anterior segment,
lens and vitreous, posterior segment examination with direct and indirect
62
ophthalmoscopy, slit lamp biomicroscopy using 90 diopter lens, intra
ocular pressure measurement were done.
All these patients were subjected to a battery of investigations
including total count, differential count, erythrocyte sedimentation rate,
chest x ray PA view, mantoux test and blood sugar. Further
investigations depends on probable etiology of posterior uveitis.
TORCH screening and Quantiferon gold were done in infectious cases.
Fundus fluorescein angiography was done in non infectious cases.
ANA, dsDNA antibody was done in suspected cases of systemic lupus
erythematosus. Optical coherent tomography was done in choroidal
neovascularization. CD4 count was done in suspected cytomegalovirus
infection. Liver function tests and renal function tests were done in
patients who required immunosuppressive therapy.
Patients were treated with topical and systemic corticosteroid
therapy in non-infectious posterior uveitis, systemic antimicrobials,
topical and systemic corticosteroids in infectious posterior uveitis
following which dose will be tapered over a period of 2 months.
Immunosuppressive therapy was given in patients not responding to
corticosteroids and those who required prolonged corticosteroid therapy.
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Proliferative retinopathy was treated with panretinal
photocoagulation. Intravitreal injection bevacizumab was given for
choroidal neovascularization. Post inflammatory glaucoma was
managed with topical antiglaucoma medications.
All patients were followed up every week for 4 weeks, every two
weeks for one month then every month for 4 months, totally of 6
months.
Improvement in visual acuity, intra ocular pressure, resolution of
vitritis and choroidal leisons were assessed during follw up.
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RESULTS AND ANALYSIS
Table 1 : Age Distribution
Age Group
Cases
No %
21 25 yrs 6 20
26 – 30 yrs 8 26.7
31 – 35 yrs 7 23.3
36 – 40 yrs 6 20
41 – 45 yrs 3 10.0
Total 30 100
Range 21 – 45  yrs
Mean 32.2  yrs
SD 6.3 yrs
In our study maximum number of cases posterior uveitis were
found to be within the age groups of 26-30 years and 31-35 years
comprising 26.7% and 23.3% respectively.
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Table 2 : Sex Distribution
Sex
Cases
No %
Male 14 46.7
Female 16 53.3
Total 30 100
Out of cases in our study 14 cases were males (46.7%), 16 cases
were females (53.3%). Not much of sexual predilection towards any
group in our study.
Table 3 : Laterality
Laterality
Cases
No %
Unilateral 15 50
Bilateral 15 50
Total 30 100
Regarding the laterality, out of 30 cases in our study 15 cases
(50%) were unilateral and 15 cases were bilateral (50%). The laterality
was equal in our study.
66
AGE DISTRIBUTION
5, 16%
9, 30%
8, 27%
5, 17%
3, 10%
21 - 25 yrs 26 - 30 yrs 31 - 35 yrs
36 - 40 yrs 41 - 45 yrs
SEX DISTRIBUTION
14, 47%16, 53%
MALE
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Table 4 : Duration and Onset
Duration No of cases Percentage
Acute 0 0
Acute recurrent 0 0
Chronic 30 100%
 In  our  study  out  of  30  cases,  all  cases  (100%)  were  of  chronic
duration of more than 6 weeks. There was no acute and acute recurrent
cases.
Table 5: Severity of posterior uveitis
Severity No. of cases Percentage
Mild 0 0%
Moderate 0 0%
Severe 30 100%
In our study out of 30 cases, all cases (100%) were of severe in nature.
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Table 6 : Aetiology of posterior uveitis
Aetiology No of cases Percentage
Infectious 18 60%
Non infectious 12 40%
Total 30 100%
In  our  study  out  of  30  cases,  18  cases  (60%)  were  of  infectious
etiology and 12 cases (40%) non infectious etiology. Infectious etiology
was more common than non infectious etiology in our study.
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LATERALITY
15, 50%
15, 50%
UNILATERAL
BILATERAL
AETIOLOGY OF POSTERIOR UVEITIS
18, 60
%
12, 40
%
Infectious
Non Infectious
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Table 7 : Aetiological Diagnosis
Aetiology
Cases
No %
Toxoplasmosis
a) Macular area
b) Extramacular area
c) Total
8
5
13
26.7
16.7
43.3
VKH Syndrome 5 16.7
Cytomegalovirus retinitis 3 10.0
SLE- Retinal Vasculitis 3 10.0
Serpiginous Choroidopathy 3 10.0
Eale’s disease 1 3.3
Tuberculosis 1 3.3
Toxocariasis 1 3.3
Total 30 100
In the aetiological analysis, 13 cases (43.3%) were of Toxoplasma
etiology, 5 cases (16.7%) of VKH Syndrome, 3 cases (10.0%) were of
serpiginous choroidopathy, 3 cases (10.0%) were of cytomegalovirus
retinitis, 3 cases (10.0%) were of SLE retinal vasculitis. Eale’s disease
was found in one case (3.3%), one case (3.3%) had Tuberculous
etiology and Toxocariasis was found in one case (3.3%).
71
AETIOLOGICAL DIAGNOSIS
ANATOMICAL CLASSIFICATION
0 10 20
Choroiditis
Retinochoroiditis
Chorioretinitis
Retinal Vasculitis
Panuveitis
2
16
3
4
5
Number of cases
0 5 10 15 20 25 30
Macular area Toxoplasmosis
Extramacular area
Toxoplasmosis
VKH Syndrome
Cytomegalovirus retinitis
SLE- Retinal Vasculitis
SerpiginousChoroidopathy
Others
26.7
16.7
16.7
10
10
10
10
Percentage of cases
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Table 8 :Anatomical classification
Anatomical
Classification
Cases
No %
Choroiditis 2 6.7
Retinochoroiditis 16 53.3
Chorioretinitis 3 10.0
Retinal Vasculitis 4 13.3
Panuveitis 5 16.7
Total 30 100
Based on anatomical classification of Posterior uveitis in our
study, 16 cases (53.3%) of cases were Retinochoroiditis, 4 cases
(13.3%) were Retinal vasculitis, 3 cases (10.0%) were Chorioretinitis, 2
cases (6.7%) were Choroiditis and 5 cases (16.7%) were found to be
Panuveitis.
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Table 9 : Aetiological analysis based Anatomical classification.
Aetiology
Choroditis
Retina
choroditis
Chorio
Retinitis
Retinal
Vasculitis
Panuveitis
No % No % No % No % No %
Toxoplasmosis
(13)
- - 13 81.25 - - - - - -
VKH Syndrome
(5)
- - - - - - - - 5 100
Serpiginous
Choroidopathy
(3)
- - - - 3 100 - - - -
SLE-Retinal
Vasculitis (3)
- - - - - - 3 75 - -
Cytomegalovirus
retinitis (3)
- - 3 18.75 - - - - - -
Eale’s disease
(1)
- - - - - - 1 25 - -
Tuberculosis (1) 1 50 - - - - - - - -
Toxocariasis (1) 1 50 - - - - - - - -
 In case of Choroiditis only 2 cases were present in our study in
that one was  Tuberculosis another was Toxocariasis. In
Retinochoroiditis 81.25% of cases were Toxoplasmosis and 18.75% of
cases were Cytomegalovirus infection. In retinal vasculitis 75% were
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due to systemic lupus erythematosus and 25% was due to Eale’s disease.
Panuveitis is mainly due to VKH Syndrome (100%).
In our study choroiditis and chorioretinitis were of infectious
origin. Retinal vasculitis was due to SLE and Eales disease.
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Table 10 :Age incidence based on anatomical classification
Age
No
of
cases
Choroditis
Retina
choroditis
Chorio
Retinitis
Retinal
Vasculitis
Panuveitis
No % No % No % No % No %
21 - 25 6 1 16.7 4 66.7 - - 1 16.7 - -
26 - 30 8 - - 4 50 - - 2 25 2 25
31 - 35 7 -- - 4 57.1 - - 1 14.3 2 28.6
36 - 40 6 - - 3 50 2 33.3 - - 1 16.7
41 - 45 3 1 33.3 1 33.3 1 33.3 - - - -
Total 30 2 6.7 16 53.3 3 10.0 4 13.3 5 16.7
In our study maximum number of cases posterior uveitis were
found to be within the age groups of 26-30 years and 31-35 years
comprising 26.7% and 23.3% respectively. Age group affected in our
study was between 21- 45 years of age.
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Table 11 :Sex incidence based on anatomical classification.
Sex
Choroditis
Retina
choroditis
Chorio
Retinitis
Retinal
Vasculitis
Panuveitis
No  % No % No % No % No %
Male 1 50 8 50 3 100 1 25 2 40
Female 1 50 8 50 - - 3 75 3 60
        In Choroiditis one case(50%) was male and one case (50%)  was
female. In Retinochoroiditis 8 cases (50%) were males and 8 cases
(50%) were females. In Chorioretinitis all cases (100%) were males. In
Retinal vasculitis one case (25%) was male and 3 cases (75%) were
females. In Panuveitis 2cases (40%) and 3 cases (60%) were females.
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Table 12 :Laterality based on anatomic classification
Laterality
Choroditis
Retina
choroditis
Chorio
Retinitis
Retinal
Vasculitis
Pan
uveitis
No % No % No % No % No %
Unilateral 2 100 13 81.25 - - - - -  -
Bilateral - - 3 18.75 3 100 4 100 5 100
       Based on anatomical classification, all cases of Choroiditis were
unilateral. In Retinochoroiditis 13 cases (81.25%) were unilateral and 3
cases (18.75%) were bilateral. In Chorioretinitis all cases were bilateral.
In Retinal vasculitis all cases were bilateral. All cases of Panuveitis were
bilateral. Bilateral retinochoroiditis were due to CMV retinitis.
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Table 13 :  Vitreous
Vitreous No of cases Percentage
Normal 7 23.3
Grade I vitreous haze 8 26.6
Grade II vitreous haze 1 3.3
Grade III vitreous haze 13 43.3
Grade IV vitreous haze 0 0
Vitreous hemorrhage 1 3.3
Total 30 100
In our study out of 30 cases, grade III vitritis was seen in 13 cases
(43.3%), grade I vitritis was seen in 8 cases (26.6%),grade II vitritis was
seen in 1 case (3.3%). Vitreous hemorrhage was seen in one case (3.3%)
and  vitreous  was  normal  in  7  cases  (23.3%).  Majority  of  cases  in  our
study were presented with grade III vitritis.
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Table 14 : Investigations
Investigations
Cases
No %
TORCH Screening, TC, DC, ESR, 17 56.7
FFA, RFT, LFT 12 40.0
Chest X Ray, Mantoux test 1 3.3
Quantiferon Gold 1 3.3
OCT 1 3.3
CD4 Count 3 10.0
ANA, anti ds DNA Antibody, RF, cANCA,
pANCA
3 10.0
In our study most common investigation required was TORCH
screening,TC, DC and ESR for 17 cases (56.7%), followed by Fundus
Fluorescein Angiography, RFT and LFT for 12 cases (40%), CD4 count
for 3 cases (10%). Other investigations, Chest X Ray, Mantoux test,
ANA, anti ds DNA Antibody, RF, cANCA, pANCA, Quantiferon Gold
and OCT were required in one case (3.3%).
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VITREOUS  HAZE
7, 23%
8, 27%
1, 3%
1, 3%
13, 44%
Normal Grade I Vitreous haze
Grade II Vitreous haze Grade III Vitreous haze
Vitreous Hemorrhage
INVESTIGATIONS
0 10
Torch Screening
FFA
CD4 Count
ANA / ds, DNA…
Others
12
3
3
3
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Table 15 : Treatment
Treatment
Cases
No %
Systemic corticosteroids 27 90
Topical mydriatics and cycloplegics 17 56.7
Topical corticosteroids 17 56.7
Anti Toxoplasma agents 13 43.3
Immunosuppressive drugs 11 36.66
Anti cytomegalovirus drugs 3 10.0
Panretinal photocoagulation 3 10.0
Anti tubercular drugs 1 3.3
Intra vitreal injection Bevacizumab 1 3.3
Anti glaucoma medications 1 3.3
In our study most common drugs used for treatment were
systemic corticosteroids, required in 27 cases (90%), followed by topical
corticosteroids, topical mydriatics and cycloplegics in 17 cases(56.7%).
Anti Toxoplasma agents were needed in 13 cases (43.3%) and
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Immunosuppressive drugs were needed in 11 cases (36.66%). Anti
cytomegalovirus drugs and panretinal photocoagulation were given for 3
cases (10%).
Other treatments like Anti tubercular drugs, Intra vitreal injection
Bevacizumab and Anti glaucoma medications were given in one case
(3.3%).
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Table 16 : Complications
Complications
Cases
No %
Cataract 4 13.3
Glaucoma 1 3.3
Proliferative Retinopathy 3 10.0
Retinal Detachment 1 3.3
Subretinal Fibrosis 1 3.3
Choroidal
Neovascularization
1 3.3
In our study, out of 30 cases of posterior uveitis, cataract was seen
in 4 cases(13.3%), proliferative retinopathy in 3 cases(10%), subretinal
fibrosis and choroidal neovascularization were seen in one case (3.3%).
Post inflammatory glaucoma was seen in one case (3.3%).
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COMPLICATIONS
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Table 17 : Visual outcome
Visual improvement No. of cases Percentage
6/6 3 10%
6/12 – 6/9 5 16.66%
4/60 – 6/36 20 66.66%
No improvement 2 6.66%
In  our  study  of  30  cases,  even  with  early  diagnosis  and  prompt
treatment only in  3 cases (10%) vision improved to 6/6 and 5 cases
(16.66%) improved to 6/12 to 6/9. In remaining 20 cases (66.66%) there
was some visual improvement that is not very significant and in 2 cases
(6.66%) there was no visual improvement.
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Table 18 : Visual Outcome based on aetiological diagnosis
Disease
Disease
Contained
No
of
cases
Visual Outcome
Remarks
Visual
ImprovementPre
Treatment
Post
Treatment
Toxoplasmosis Yes
5 6/36– 6/24 6/12 – 6/9
Extra Macular
area
Improved
8
1/2/60–
2/60
6/60– 6/36
Macular
involvement
Improved
VKH Syndrome Yes
3 HM – 6/36 6/12 – 6/6 -
Improved
1 1/60 1/60
Choroidal
neovascularization
Not Improved
1 3/60 6/24
Subretional
fibrosis
Improved
Cytomegalovirus
retinitis
Yes 3 HM – 3/60
4/60 –
6/60
Macular
involvement
Improved
Serpiginous
Choroidopathy
Yes 3
4/60 –
6/36
6/36 –
6/12
Chorioretinal
atrophy
Improved
SLE – retinal
Vasculitis
Yes 3
1/60 –
4/60
6/60 –
6/36
Proliferative
retinopathy
Improved
Eale’s disease Yes 1 HM 6/24
Proliferative
Retinopathy
Improved
Tuberculosis Yes 1 1/60 6/36 -
Improved
Toxocariasis Yes 1 3/60 1/60
Tractional Retinal
Detachment
Not Improved
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In  our  study  out  of  13  cases  of  Toxoplasmosis,  5  cases  were
involved the extramacular area with good visual outcome , vision
improved to 6/12 to 6/9. 8 cases were showed macular involvement with
less improvement in vision in the range of 6/60 to6/36.
           In VKH Syndrome, out of 5 cases 3 cases were improved vision
significantly 6/9 to 6/6. One case had subretinal fibrosis in macular area
with  vision  improving  to  6/24.  In  one  case  was  not  improved  due  to
choroidal neovascularization.
  In cytomegalovirus infection there was only mild improvement
in vision (4/60 to6/60) due to macular involvement. In serpiginous
choroidopathy visual outcome was  affected by chorioretinal atrophy in
macular area, improved  upto 6/36 to 6/12.
             In Retinal vasculitis due to SLE (6/60 to 6/36) and in Eales
disease (6/24)visual outcome was affected by proliferative retinopathy.
In tuberculosis vision was improved to 6/36 and no complications.
              In Toxocariasis vision was not improved (1/60) due to
development of tractional retinal detachment.
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Table:19 Cause for poor visual outcome
Cause No. of cases Percentage
Chorioratinal atrophy
in macula
14 46.66%
Proliferative
retinopathy
3 10%
CNVM 1 3.33%
Sub retinal fibrosis 1 3.33%
Tractional Retinal
Detachment
1 3.33%
In our study, the most common cause for poor visual outcome is
chorioretinal atrophy (46.66%) seen in 14 cases followed by
proliferative retinopathy seen in 3 cases (10%). Others were CNVM,
subretinal fibrosis and tractional retinal detachment seen in 3.33% of
cases.
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Table 20 : Sequelae and Complications
Pathology Remarks No. of cases percentage
Structural
damage
Chorioretinal
atrophy
14 46.66%
Complication CNVM,
subretinal
fibrosis,
tractional retinal
detachment,
proliferative
retinopathy
6 20%
In our study, poor visual outcome due to structural damage (
chorioretinal atrophy) seen in 14 cases  (46.66%) and due to
complications were (20%)
In our study, Structural damage caused by the disease was more
common than the complications.
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Statistical Tools
The information collected regarding all the selected cases were
recorded in a Master Chart. Data analysis was done with the help of
computer using Epidemiological Information Package (EPI 2010)
developed by Centre for Disease Control, Atlanta.
Using this software range, frequencies, percentages, means,
standard deviations, chi square, ‘t’ value and  'p'  values were calculated.
‘t’  test was used to test the significance of difference between
quantitative variables and  Yate’s and Fisher’s chi square tests for
qualitative variables. A 'p' value less than 0.05 is taken to denote
significant relationship.
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DISCUSSION
In our study of 30 cases of Posterior Uveitis, it was observed that
posterior uveitis is more common in the age group of 26 to 35 years. Sex
incidence is almost equal in males and females. Unilateral and bilateral
cases are equal in ocurrence. Allof the cases were of chronic duration.
On analyzing the aetiology of posterior uveitis, in our study
majority of cases were found to be due to toxoplasmosis (43.3%),
followed by VKH syndrome (16.7%). Toxoplasmosis was the most
common infectious etiology found in our study.
Anatomical classification
In  our  study  majority  of  cases  were  Retinochoroiditis  (53.3%),
followed by Panuveitis (16.7%), Retinal vasculitis (13.3%),
Chorioretinitis (10%) and Choroiditis(6.7%).
Aetiological analysis
In our study, aetiological analysis of posterior uveitis showed that
majority of cases were of Toxoplasmosis(43.3%), followed by VKH
syndrome.
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Retinal vasculitis with Systemic Lupus Erythematosus were
present in3 cases(females), 2 out of thatwere getting treatment at
Rheumatology department,Government General Hospital (GGH) with
systemic corticosteroids for  the past  6 months with ANA anti  ds DNA
antibody positivity. One case was presented to our hospital with
defective vision and Rheumatoogy workup done at rheumatology
department GGH, found to be ANA and anti ds DNA antibody
positivity and started on systemic corticosteroids.
3 cases were cytomegalovirus retinitis, out of that one case was
on treatment with anti retroviral drugs for the past 2 months in ART
centre with low CD4 count. Other 2 cases were presented to our institute
with defective vision and referred to ART centre for evaluation found to
be HIV positive with low CD4 levels and started on anti retroviral
therapy.
Tuberculous etiology was found in one case with quantiferon gold
positivity and sent to Thoracic medicine department at GGH for
evaluation and treated with antituberculous drugs and systemic
corticosteroids.
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Clinical presentation
In our study, posterior uveitis is more common in age group of 26
– 35 years. Majority of cases of infectious posterior uveitis were
unilateral and non infectious posterior uveitis and panuveitis cases were
bilateral.
Complications
Since the main reason for poor visual outcomeis the structural
damage caused by the disease process, there is no significant visual
improvement even after the complete remission of the disease.
In our study cataract was present in 4 cases (13.3%), mainly in
cases of VKH syndrome.3 cases were presented with proliferative
retinopathy, 2 out of that were due to systemic lupus erythematosus with
retinal vasculitis, one was Eales disease.
Post inflammatory glaucoma was present in one case of VKH
syndrome. Subretinal fibrosis was present in one case and choroidal
neovascularization was present in another case of VKH syndrome.
Retinal detachment was present in one case of toxocariasis.
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Treatment
In our study the most common drugs used for treatment is
systemic and topical corticosteroids followed by topical mydriatrics and
cycloplegics and anti toxoplasma agents.
Since all cases of posterior uveitis are of chronic in nature,
Immunomodulators are used in 11 cases (36.66%) as steroid sparing
agents in non infectious posterior uveitis and retinal vasculitis.
In our study, toxoplasmosis cases were treated with anti
toxoplasma agents and systemic corticosteroid. CMV retinitis patients
were treated  with anti CMV agents. Serpiginous choriodopathy, SLE
with retinal vasculitis and Eales disease patients are treated with
systemic corticosteroid agents.
VKH patients were treated with topical corticosteroids, mydriatics
and cycloplegics, systemic corticosteroids and Immune modulators.
Immuno modulator therapy was given in VKH syndrome in Serpiginous
choroidopathy and SLE with retinal vasculitis.
Proliferative retinopathy cases were treated with Panretinal
photocoagulation, secondary glaucoma was treated with anti glaucoma
agents and choroidal neovascularization was treated with intra vitreal
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bevacizumab.Since cataract was in early stage, without obstructing the
visual axis they were not treated.
Visual outcome
In  our  study,  due  to  early  diagnosis  and  prompt  treatment  the
disease  was  adequately  controlled   in  all  cases.  But  only  26.66%  of
patients obtained significant visual improvement. Other  66.66% of
patients there is some visual improvement that is not very significant.
The main reason for poor visual outcome was chorioretinal atrophy in
the macula, the structural damage caused by the disease followed by the
complications namely sub retinal fibrosis and  proliferative retinopathy.
 In  6.6%  of  patients,  there  was  no  visual  improvement  due  to
complications mainly  choroidal neovascularization  and  tractional
retinal detachment. In choroidal neovascularization, after treatment
scarring was occurred but there was no visual improvement.
Out  of  13  cases  of  Toxoplasmosis,  5  cases  were  involved  the
extramacular area with good visual outcome and 8 cases were showed
macular involvement with less improvement in vision.
 In VKH Syndrome, out of 5 cases 3 cases were improved vision
significantly . One case had subretinal fibrosis in macular area  with
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vision improving to 6/24. In one case vision was not improved due to
choroidal neovascularization.
 In cytomegalovirus infection there was only mild improvement in
vision due to macular involvement. In serpiginous choroidopathy visual
outcome was affected by chorioretinal atrophy in macular area.
In  Retinal  vasculitis  due  to  SLE  and  in  Eales  disease  visual
outcome was affected by proliferative retinopathy. In tuberculosis vision
was improved significantly.
In Toxocariasis vision was not improved due to development of
tractional retinal detachment.
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CONCLUSION
? Posterior uveitis is a serious disease associated with vision
threatening complications.
? Posterior  uveitis  is  more  common  in  the  age  group  of   26-35
years.
? All cases of posterior uveitis is of chronic duration.
? All cases of posterior uveitis are severe in nature.
? Retinochoroiditis is the most common anatomical type
comprising more than half of the cases.
? Posterior uveitis due to infectious causes are common than non
infectious causes.
? Toxoplasma is the most common aetiology detected in posterior
uveitis.
? Toxoplasma is the major infectious aetiology found in posterior
uveitis.
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? In non infectious causes Vogt Koyanagi Harada syndrome,
vasculitis due to collagen vascular diseases are the common
causes.
? With prompt treatment the disease is controlled in all cases of
posterior uveitis.
? Corticosteroids are the most common drugs used for  treatment of
posterior uveitis.
? Immuno modulators are  used as a steroid sparing agents in non
infectious posterior uveitis and retinal vasculitis.
? Despite adequate control of the disease the visual outcome is
comparatively poor in posterior uveitis.
? The main reason for poor visual prognosis is the structural
damage ( chorioretinal atrophy in the macula) caused by the
disease followed by complications.
? In posterior uveitis visual prognosis depends upon the aetiology,
area of involvement and complications.
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UVEITIS PROFORMA
Name :                                   age/sex:                      date:
                                                                                 Phone no:
                                                                                 Occupation:
                                                                                  Address:
Complaints:
1) Symptoms of anterior segment involvement
Pain
Redness
Photophobia
2) floaters U/L, B/L
3) Defective vision-onset  sudden / insidious
                           -painless / painful
h/o joint pain
trauma
surgery
history s/o focal sepsis ENT
                                     Dental caries
h/o contact with TB/leprosy/ pet animals
h/o previous episodes
age at onset
no of episodes
response to treatment
h/o DM/ HT
h/o systemic diseases( rheumatoid arthritis& other connective tissue
disorders)
family history similar illness
Other significant history
Systemic examination
Pulse :     /min                       BP :         mmHg
Cardiovascular system:
Respiratory system:
Gastrointestinal system:
Central nervous system:
Ocular Examination
UCVA                     RE                                        LE
BCVA                     RE                                         LE
IOP                         RE                                         LE
Slit lamp examination
Anterior segment RE LE
Lids edema
Conjunctiva ccc
Cornea- KPs fine/mutton
fat/pigmented
AC-
cells/flare/hypopyon/shallow
ac/Peripheral antrsynaechiae
Iris-CPN/atrophic patches/iris
bombe/koeppes/busaccas
nodules
Pupil-
RTL/RAPD/irregular/festooned
pupil/occulusiopupillae/seclusion
pupillae
Lens-posterior synaechiae/iris
pigment over lens/cataract
Anterior vitreous-cells/opacities
Fundus IDO
Fundus RE LE
Vitritis grade
I/II/III/IV
PVD
Choroidits patch-
yellowish ill defined
patch/atrophic
pigmented sharply
defined patch
Retinal edema
Sheathing of vessels
Disc edema
Retinal
hemorrhages
Cystoid macular
edema
Snowbanking/snow
ball opacities
Fundus diagram:RE                                            LE:
Investigations
Fundus photo:
Hb
TC,DC,ESR,Mantouxtest,Chest X ray,RBS,Urinealb/sugar,VDRL/RA
factor/ACE/ANA factor and X ray sacro iliac joints
FFA:
B SCAN (if necessary):
TORCH screening
ENT opinion
Dental opinion
Rheumatology opinion
Chest physician opinion
Diagnosis  - Acute/ Acute recurrent /Chronic
                       -Unilateral/Bilateral
                       -Posterior uveitis
                       -Aetiology
Treatment
Topical corticosteroids
Topical mydriatics and cycloplegics
Oral corticosteroids
Immunomodulators
Others :
Follow up
BCVA
Intraocular pressure
Healing of leisons
B SCAN (if necessary)
RE LE RE LE RE LE RE LE RE LE
1 Pradeep Kumar 25 / M DV RE -2 Yrs
DV LE x 1 WK
6/60 6/24 - Cells1+, Flare 1+ 1 4 1f 1d 1 1b 5,2, 1a, 1b 6/60 6/6
2 Rajan 36 / M DV BE x 1 WK 3/60 3/60 CCC, KP, Cell 2 + , Flare 2 + CCC, KP, Cell 2 + , Flare 2 + 2 2 2 2 2 2 1a, 1b, 2, 4 6/9 6/24
3 Kuppu 45 / F F, DV - RE x 1 Month 1/60 6/60 - - 3 1 6 N 3, 4 6 2, 6 6/36 6/60
4 Girirajan 37 / M DV BE x 2 Months 6/36 5/60 - - 1 1 3 3 2 3 2,4 6/24 6/36
5 Varalaxmi 36 / F F, DV LE x 1 Month 6/6 1/60 - Cells1+, Flare 1+ 1 4 N 1a 1 1a 2,5 6/6 6/36
6 Muniyammal 35 / F DV BE x 1 Month HM 4/60 - - 2 2 4b 4c 1, 6 4 10 3/60 6/60
7 Venkatesan 21 / M F, DV LE x 1 Month 6/6 6/24 - Cells1+, Flare 1+ 1 4 N 1d 1 1b 1a, 1b, 2, 5 6/6 6/12
8 Sridhar 30 / M F,DV RE 1 month 6/36 6/6 - - 4 1 1c N 1 1b 1a, 1b, 2, 5 6/12 6/6
9 Vijaya 30 / F DV BE x 2 Wks 6/60 HM CCC, KP + , Cells ++, Flare 2 +,
PAS +,
CCC, KP +, Cells 2 +, Flare 2 + 2 2 2 2 2 2 1a,1b,2,3,4,9 6/24 6/12
10 Manikam 35 / M DV LE x 1 Wk 6/18 HM - - 1 6 8a 8b 2 8 2, 7 6/18 6/24
11 Rajesh 30 / M DV LE x 1 Month 6/6 3/60 - - 1 1 N 7 1 7 2 6/6 1/60
12 Vijayalakshmi 35 / F F, DV LE x 1 Month 6/6 6/36 - Cells1+, Flare 1+ 7 4 N 1c 1 1b 1a, 1b, 2, 5 6/6 6/12
13 Radha 38 / F DV LE x 2 Months 6/18 1/2 / 60 - - 7 2 - 4a 1, 6 4 10 6/18 4/60
14 Uma 25 / F F, DV RE x 2 Wks 1/60 6/6 Cells1+, Flare 1+ - 4 1 - 1c 1 1b 1a, 1b, 2, 5 6/12 6/6
15 Kathiresan 30 / M F, DV LE x 1 Month 1/2/60 6/6 - Cells1+, Flare 1+ 1 4 N 1a 1 1a 1a, 1b, 2, 5 6/60 6/6
16 Maheshwari 34 / F DV BE x 2 Wks 6/60 6/36 CCC, KP, Cell 2 + , Flare 2 + CCC, KP, Cell 2 + , Flare 2 + 2 2 2 2 2 2 1a, 1b, 2, 4 6/9 6/6
17 Susella 30 / F DV BE x 1 Month 3/60 2/60 - - - - 5 5 2,7 5 2,7 6/36 6/60
18 Kaniyappan 45 / M DV LE x 3 Months 6/18 HM - - - 2 N 4a 1, 6 4 10 6/18 3/60
19 Annamalai 40 / M DV BE x 2 Months 4/ 60 6/60 - - - - 3 3 2 3 2,4 6/24 6/36
20 Palani 29 / M DV BE x 2 Wks 4/60 4/60 CCC, KP +Cells 2 +, Flare 2 + , CCC +, KP +, Cells 2 +, Flare 2 + 2 2 2 2 2 2 1a, 1b, 2 ,4 6/9 6/9
21 Kumari 24 / F DV BE x 1 Month 3/60 4/60 - - - - 5 5 2, 7 5 2 6/36 6/24
22 Manivannan 31 / M F, DV RE  x 1 Month 2/60 6/6 Cells1+, Flare 1+ - 4 1 1a N 1 1a 1a, 1b, 2, 5 6/36 6/6
23 Rangan 42 / M DV BE x 2 Months 6/60 6/36 ` - - - 3 3 2 3 2,4 6/36 6/12
24 Mariyammal 35 / F DV BE x 1 Wk 2/60 1/60 CCC, KP, Cell 2 + , Flare 2 + CCC +, KP +, Cells 2 +, Flare 2 + 2 2 2 2 2, 5 2 1a, 1b, 2, 4, 9 1/60 6/9
25 Vasantha 28 / F DV BE x 1 Month 6/60 4/60 - - - - 5 5 2, 7 5 2,7 6/60 6/36
26 Lakshmi 26 / F F, DV LE x 1 Wk 6/6 1/60 - Cells1+, Flare 1+ - 4 N 1a 1 1a 1a, 1b, 2, 5 6/6 4/60
27 Rajeswari 21 / F F, DV RE x 2 Wks 1/60 6/6 Cells1+, Flare 1+ - 4 - 1a - 1 1a 1a, 1b, 2, 5 6/6 6/36
28 Megala 28 / F F, DV LE x 2 Wks 6/6 2/60 - Cells1+, Flare 1+ - 4 N 1a 1 1a 1a, 1b, 2, 5 6/6 6/36
29 Sekar 34 / M F, DV RE x 2 Wks 1/60 6/6 Cells1+, Flare 1+ - 4 - 1a N 1 1a 1a, 1b, 2, 5 6/60 6/6
30 Ambiga 31 / F F, DV LE x 1 Month 6/6 1/60 - - - 4 N 1a 1 1a 1a, 1b, 2, 5 6/6 6/60
MASTER CHART
VISION
S.No NAME AGE/ SEX COMPLAINTS / DURATION
ANTERIOR SEGMENT VITREOUS FUNDUS FINAL VISION
INVESTIGATION DIAGNOSIS TREATMENT
KEY TO MASTER CHART
RE   – Right eye
LE   – Left eye
BE   – Both eyes
F      – Floaters
DV   –Defective vision
CCC – Circum Corneal Congestion
Vitreous
1- Normal
2- Grade I vitreous haze
3- Grade II vitreous haze
4- Grade III vitreous haze
5- Grade IV vitreous haze
6- Vitreous haemorrhage
Fundus
1) 1a -  Focal yellow white retinal lesion in the macula.
1b -  Focal yellow white retinal lesion adjacent to pigmented
chorioretinal  scar in the  acula.
1c -  Focal yellow white retinal lesion above supertemporal arcade
1d -  Focal yellow white retinal lesion below supertemporal arcade
1e -  Focal yellow white retinal lesion superior to macula and
below the supertemporal arcade.
1f  -  pigmented chorioretinal atrophic scar in the macula.
2  -  Multiple serous retinal detachments with underlying choroidal
thickening and optic disc edema.
3  -  Geographic yellow white subretinal patches with indistinct
margins from the disc running centrifugally extending to
posterior pole and macula.
4 4a- Dense white, well demarcated geographic areas of retinal
opacification associated with retinal hemorrhages in the
superotemporal arcade and macula.
4b -  Dense white, well demarcated geographic areas of retinal
opacification associated with retinal hemorrhages in brushfire
like extension along the course of vascular arcade with
involvement of optic disc and macula.
4c -  Granular opacification in the periphery.
5 5a -  Cotton wool spots and flame shaped hemorrhages,hard
exudates in superotemporal and inferotemporal quadrant.
5b -  Cotton wool spots and flame shaped hemorrhages,hard
exudates and neovascularization elsewhere in superotemporal
and inferotemporal quadrant
6 -  Large solitary yellowish choroidal granuloma about 2 disc
diameters in size seen in inferonasal quadrant.
7  -  Elevated white retinal lesion in superotemporal periphery
associated with fibrous band extending to macula.
8 8a -  vitreous haemorrhage
8b -  peripheral vascular sheathing in the supertemporal quadrant.
Diagnosis
1-Toxoplasmosis a) Macular area
                  b) Extramacular area
2- Vogt- Koyanagi- Harada Syndrome
3- Serpiginouschoroiditis
4- Cytomegalovirus retinitis
5- Systemic lupus erythematosus with retinal vasculitis
6- Tuberculosis
7- toxocariasis
8-Eales disease
Investigations
1- TORCH screening, Total Count, Differential Count, Erythrocyte
Sedimentation Rate
2- Fundus Fluorescein Angiography, RFT, LFT
3- chest x ray and Mantoux test
4- Quantiferon gold
5- Optical Coherence Tomography
6- Antinuclear antibody(ANA), anti double stranded DNA antibody(ds
DNA), Rheumatoid factor(RF) and anti neutrophil cytoplasmic
antibody (c ANCA, p ANCA)
Treatment
1- Topical corticosteroids, topical mydriatics and cycloplegics
2- Oral prednisolone
3- Intravenous Methyl prednisolone
4- immuomodulators
5- Anti Toxoplasma agents
6- Anti tubercular drugs
7- Panretinal photocoagulation
8- Intravitreal injection Bevacizumab
9- Antiglaucoma medications
10-Anticytomegalovirus drugs
ABBREVIATIONS
CMV        - cytomegalovirus
VKH         - Vogt Koyanagi Harada syndrome
IUSG         - International Uveitis Study Group
ELISA       - Enzyme Linked Immuno Sorbent Assay
TB             - Tuberculosis
CNV          - Choroidal neovascularization
SLE           - Systemic lupus erythematosus
FFA           - Fundus Fluorescein Angiography
RPE           - Retinal Pigment Epithelium
HLA          - Human Leucocyte Antigen
VDRL        - Venereal Diseases Research Laboratory
RPR           - Rapid Plasma Reagin
FTA- ABS - Fluorescent Treponemal Antibody Absorption test
HSV           - Herpes Simplex Virus
VZV           - Varicella Zoster Virus
HIV            - Human immunodeficiency Virus
AIDS          - Acquired Immunodeficiency Syndrome
CT              - Computed Tomography
IOP             - Intra Ocular Pressure
ATT            - Anti Tubercular Therapy
TORCH         - Toxoplasma
                       - Others
                       - Rubella
                       - Cytomegalovirus
                       - Herpes Simplex Virus
TC                  - Total Count
DC                 - Differential Count
ESR               - Erythrocyte Sedimentation Rate
RFT               - Renal Function Tests
LFT               -  Liver Function Tests
IDO               -  Indirect Ophthalmoscopy
